On Friday, Verona Pharma Plc ADR (NASDAQ: VRNA) was 4.72% up from the session before settling in for the closing price of $21.60. A 52-week range for VRNA has been $11.39 – $23.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -39.77% over the past five years. When this article was written, the company’s average yearly earnings per share was at -626.67%. With a float of $62.41 million, this company’s outstanding shares have now reached $80.44 million.
Let’s look at the performance matrix of the company that is accounted for 79 employees.
Verona Pharma Plc ADR (VRNA) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Verona Pharma Plc ADR stocks. The insider ownership of Verona Pharma Plc ADR is 23.03%, while institutional ownership is 62.21%. The most recent insider transaction that took place on May 03 ’24, was worth 71,032. In this transaction Chief Medical Officer of this company sold 36,248 shares at a rate of $1.96, taking the stock ownership to the 2,621,552 shares. Before that another transaction happened on Feb 05 ’24, when Company’s Chief Medical Officer sold 36,248 for $2.22, making the entire transaction worth $80,503. This insider now owns 2,731,624 shares in total.
Verona Pharma Plc ADR (VRNA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.58 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -626.67% per share during the next fiscal year.
Verona Pharma Plc ADR (NASDAQ: VRNA) Trading Performance Indicators
You can see what Verona Pharma Plc ADR (VRNA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.61.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.56, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.37 in one year’s time.
Technical Analysis of Verona Pharma Plc ADR (VRNA)
Verona Pharma Plc ADR (NASDAQ: VRNA) saw its 5-day average volume 1.08 million, a positive change from its year-to-date volume of 0.86 million. As of the previous 9 days, the stock’s Stochastic %D was 55.46%. Additionally, its Average True Range was 1.50.
During the past 100 days, Verona Pharma Plc ADR’s (VRNA) raw stochastic average was set at 91.08%, which indicates a significant increase from 80.75% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.39% in the past 14 days, which was higher than the 62.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.77, while its 200-day Moving Average is $16.37. Nevertheless, the first resistance level for the watch stands at $23.63 in the near term. At $24.63, the stock is likely to face the second major resistance level. The third major resistance level sits at $25.67. If the price goes on to break the first support level at $21.59, it is likely to go to the next support level at $20.55. Assuming the price breaks the second support level, the third support level stands at $19.55.
Verona Pharma Plc ADR (NASDAQ: VRNA) Key Stats
There are 79,480K outstanding shares of the company, which has a market capitalization of 1.83 billion. As of now, sales total 0 K while income totals -54,370 K. Its latest quarter income was 0 K while its last quarter net income were -25,790 K.
